Viking Therapeutics, Inc. (VKTX) |
68.69 -0.17 (-0.25%) 04-26 12:38 |
Open: | 69 |
High: | 71.5 |
Low: | 68.22 |
Volume: | 1,524,249 |
Market Cap: | 7,512(M) |
PE Ratio: | -74.66 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 89.10 |
Resistance 1: | 78.61 |
Pivot price: | 68.05 |
Support 1: | 61.64 |
Support 2: | 51.28 |
52w High: | 99.41 |
52w Low: | 8.28 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
EPS | -0.910 |
Book Value | 3.480 |
PEG Ratio | -1.44 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -23.5 |
Return on Equity (ttm) | -34.8 |
Fri, 26 Apr 2024
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 Earnings Call Transcript - Yahoo Finance
Wed, 24 Apr 2024
Viking Therapeutics down 4% despite quarterly bottom line beat - Seeking Alpha
Wed, 24 Apr 2024
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO - Viking Therapeutics (NASDAQ:VK - Benzinga
Wed, 24 Apr 2024
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
Mon, 22 Apr 2024
Looking At Viking Therapeutics's Recent Unusual Options Activity - Viking Therapeutics (NASDAQ:VKTX) - Benzinga
Fri, 19 Apr 2024
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |